This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.
Ocugen (OCGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Ocugen (OCGN) closed at $6.71 in the latest trading session, marking a -1.61% move from the prior day.
Zacks.com featured highlights include: Manchester United, Carrols Restaurant, Astronics Corp and Ocugen
by Zacks Equity Research
Zacks.com featured highlights include: Manchester United, Carrols Restaurant, Astronics Corp and Ocugen
Sell These 4 Toxic Stocks to Avoid Losing Money Overnight
by Rimmi Singhi
Toxic stocks are vulnerable to external shocks, burdened with high debt and bound to result in loss for investors over time. Discard such stocks from your portfolio right away to avoid losses.
Company News for Jul 7, 2021
by Zacks Equity Research
Companies In The News Are: AMZN, MSFT, PFE, AMC, OCGN.
Is the Options Market Predicting a Spike in Ocugen (OCGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US
by Zacks Equity Research
Ocugen (OCGN) selects Jubilant HollisterStier as its manufacturing partner for its COVID-19 vaccine candidate, Covaxin, in the United States and Canada.
Company News for Jun 16, 2021
by Zacks Equity Research
Companies In The News Are: BA, MSTR, OCGN, F
Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks
by Zacks Equity Research
Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. Shares fall.
Are Options Traders Betting on a Big Move in Ocugen (OCGN) Stock?
by Aditi Saraogi
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Ocugen (OCGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year
by Zacks Equity Research
Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.
The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioNTech, Ocugen, Rubius Therapeutics and Entera Bio
4 Biotech Stocks That Have Already Doubled This Year So Far
by Kinjel Shah
Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.
Is the Options Market Predicting a Spike in Ocugen (OCGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Ocugen (OCGN) Miss Earnings & Revenues Estimates in Q1
by Zacks Equity Research
Ocugen (OCGN) miss earnings and revenues estimates in the first quarter of 2021. Stock down.
Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN
by Kinjel Shah
Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide update related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports first-quarter 2021 results.
Ocugen (OCGN) Up on Positive Data for COVID-19 Vaccine Candidate
by Zacks Equity Research
Ocugen (OCGN) gains as partner Bharat Biotech shared positive results of the second interim analysis of its phase III study of COVAXIN.
Are Options Traders Betting on a Big Move in Ocugen (OCGN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.
Ocugen (OCGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Ocugen (OCGN) closed the most recent trading day at $6.70, moving -1.33% from the previous trading session.
Ocugen (OCGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Ocugen (OCGN) closed the most recent trading day at $9.90, moving -1% from the previous trading session.
Ocugen (OCGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Ocugen (OCGN) closed at $8.63 in the latest trading session, marking a -1.26% move from the prior day.
Ocugen (OCGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) will provide updates on its pipeline when it reports fourth-quarter 2020 results.